The Institute of Bioorganic Chemistry offers consumers a range of hemosorbents for detoxification of the body in septic conditions by selectively removing lipopolysaccharide from the blood of gram-negative microorganisms (sepsis, peritonitis, pneumonia, burn disease, etc.) under a manufacturing agreement and is looking for partners interested in a distribution services agreement.

Hemosorbents (Hemo-Proteazsorb, LPS-Hemo, Anti-IgE-Hemo) are medical products that are designed to remove harmful substances of various nature from the blood for certain diseases (oncological, autoimmune, infectious, allergic, etc.).

Hemosorbent "LPS-Hemo" is intended for detoxification of the body in septic conditions by selectively removing lipopolysaccharide of gram-negative microorganisms from the blood (sepsis, peritonitis, pneumonia, burn disease, etc.), as well as for the prevention of septic complications involving gram-negative flora after organ and tissue transplantation; specific capacity for E. coli endotoxin is at least 250,000 EU (for a 75 ml column).

Hemosorbent "Hemo-Proteazsorb" is used for selective removal of active forms of proteinases and/or their complexes with inhibitors from whole blood, plasma in order to detoxify the body in pathological conditions accompanied by activation of proteolysis and enzymatic intoxication (pancreatitis, peritonitis, sepsis, etc.); specific sorption capacity for trypsin is 0.9 mg/ml. Hemosorbent "Anti-IgE-Hemo" is used to remove immunoglobulins of class E, G from blood / plasma. It is used in efferent medicine for the treatment of bronchial asthma, atopic diseases, seasonal and food allergies. In immunology for the treatment of autoimmune diseases, removal of autoantibodies of class G.

Hemosorbent "Antilipoprotein" is designed to reduce the level of blood lipoproteins in dyslipidemia of various origins. Specifically binds low and very low density lipoproteins, which are the most atherogenic class of blood lipids. Reducing the above lipoproteins reduces the risk of developing complications of atherosclerosis in patients with dyslipidemia.

Scope: clinical medicine, medicine of disasters and emergency situations.

Technologies for the production of biospecific hemosorbents for the clinical therapy of endogenous diseases have been developed. All hemosorbents have successfully passed clinical trials, according to the results of which registration certificates of the Ministry of Health of the Republic of Belarus were received.


Information is posted in  Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), p. 174-176. (in Russian)

Bioaffinity hemosorbents provide the possibility of providing highly specialized medical care at the stage of patient transportation or directly at the site of injury using portable equipment. All hemosorbents have high bio- and hemocompatibility, high binding activity, and have pronounced clinical and medical-biological effects when biospecific sorption is included in the complex therapy of diseases. Biospecific sorbents of domestic development do not have the properties of non-specific sorption inherent in foreign analogues. Single use, mass exchange modules of 75, 180 ml, technological application, low cost, long shelf life determine the competitiveness of hemosorbents in the domestic and world markets.

The use of domestically produced hemosorbents in the complex therapy of patients leads to a reduction in the need for expensive drugs, a decrease in disability, and a reduction in the length of stay of patients in hospitals.

The Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus is the only manufacturer of biospecific sorbents in the Republic of Belarus, therefore the pricing concept for hemosorbents is based on the approach of setting prices based on cost price with the pricing direction of “setting prices to stimulate sales”.

A production area was created and 4,726 hemosorbents "Hemo-Proteazsorb" were produced, "LPS-Hemo", "Anti-IgE-Hemo".

The following trademarks are registered:
ЛПС-Гемо (LPS-Hemo)
Registration number: 58236, registration date: 27.04.2016.
Протеазсорб-Гемо (Proteazsorb-Hemo)
Registration number: 58237, registration date: 27.04.2016.
Анти-ИГЕ-Гемо (Anti-IgE-Hemo)
Registration number: 58235, registration date: 27.04.2016

Currently, the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus is one of the well-known scientific centers for the study of the most important biopolymers (proteins, enzymes, nucleic acids) and low-molecular bioregulators (steroid hormones of humans, insects and plants, peptides, phospholipids, prostaglandins and their synthetic analogues).

Main areas of activity:
- fundamental and applied research in the field of chemistry, structure and function of biopolymers and low-molecular bioregulators, including proteins, nucleic acids and their components, phospholipids, steroids, prostaglandins, brassinosteroids, ecdysteroids;
- development and pilot production of immunochemical and molecular biological reagent kits for medical and veterinary diagnostics;
- development and production of pharmaceutical substances, hormonal drugs and biospecific hemosorbents;
- development of technologies for the production and use of growth stimulants and plant protection products;
- experimental and clinical pharmacology, pharmacy and drug technology, toxicology, human and animal biochemistry, biomedical and pharmaceutical chemistry;
- preclinical, bioequivalent and pharmaceutical testing.

Main research areas:
- organic and bioorganic chemistry of low-molecular bioregulators (steroids, peptides, prostaglandins, lipids, nucleosides and nucleotides) and the most important biopolymers, including proteins and nucleic acids, establishing patterns of their functioning in living systems;
- development of new chemical, chemical-enzymatic and genetic engineering methods for obtaining biopolymers and low-molecular bioregulators and their analogues in order to create drugs for medicine and agriculture on their basis;
- study of the structure, physicochemical properties and biological activity of natural biomolecules and their analogues, establishing the relationship between their structure and biological activity, development of scientific principles for targeted search for substances with predictable biological activity;
- study of the structure, function and mechanism of action of enzyme systems of biosynthesis and metabolism of the most important natural bioregulators and xenobiotics;
- development of technologies for the production of reagents for medical diagnostics, drugs and chemical plant protection products.

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For the pilot production of the developed products (hemosorbents, recombinant enzyme preparations, immunochemical reagents, oxyphytosterols, etc.), the institute has created 5 pilot production sites.

The results of fundamental and applied research on methods and means of plant protection against diseases, insects, weeds and other adverse environmental factors that are safe for humans and the biosphere as a whole served as the foundation for developing methods for obtaining new plant growth stimulants, pheromone compositions (pheromones of the codling moth LP-U and the miller moth), active ingredients of pesticides (analogues of the herbicide Grasp and the insecticide Confidor), preparative forms of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of valid patents, laboratory technological and pilot-industrial regulations, technical specifications, and trademarks. There are license agreements in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents and pesticides to manufacturers.

The Institute of Bioorganic Chemistry successfully develops international relations in the main areas of its research. Currently, the institute conducts joint research with scientific institutes in the CIS countries, Germany, the USA, Canada, Sweden, Finland, Denmark, Holland, Vietnam and other countries.

Consumers interested in purchasing a range of hemosorbents for detoxification of the body in septic conditions by selectively removing gram-negative microorganisms from the blood of lipopolysaccharide (sepsis, peritonitis, pneumonia, burn disease, etc.) under a manufacturing agreement.

Partners interested in purchasing a range of hemosorbents for detoxification of the body in septic conditions by selectively removing gram-negative microorganisms from the blood of lipopolysaccharide (sepsis, peritonitis, pneumonia, burn disease, etc.) under a distribution services agreement.